FDA Approves Abiraterone Acetate to Treat Metastatic Castration-Resistant Prostate Cancer

On May 23, the FDA approved abiraterone acetate (Yonsa, Sun Pharmaceutical Industries Ltd.) in combination with methylprednisolone for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Read the Sun Pharma press release here.

Posted 5/24/2018